フィネレノン
フィネレノン 物理性質
- 沸点 :
- 554.7±50.0 °C(Predicted)
- 比重(密度) :
- 1.29±0.1 g/cm3(Predicted)
- 貯蔵温度 :
- -20°C
- 溶解性:
- DMF: 10 mg/ml DMSO: 3 mg/ml Ethanol: insol PBS (pH 7.2): insol
- 酸解離定数(Pka):
- 14.76±0.40(Predicted)
- 外見 :
- solid
- 色:
- White to off-white
- 極大吸収波長 (λmax):
- 255 nm
- InChI:
- InChI=1S/C21H22N4O3/c1-5-28-21-18-17(14-7-6-13(9-22)8-15(14)27-4)16(20(23)26)12(3)25-19(18)11(2)10-24-21/h6-8,10,17,25H,5H2,1-4H3,(H2,23,26)/t17-/m1/s1
- InChIKey:
- BTBHLEZXCOBLCY-QGZVFWFLSA-N
- SMILES:
- N1C2=C(C(OCC)=NC=C2C)[C@H](C2=CC=C(C#N)C=C2OC)C(C(N)=O)=C1C
安全性情報
- リスクと安全性に関する声明
- 危険有害性情報のコード(GHS)
フィネレノン 価格
| メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
フィネレノン 化学特性,用途語,生産方法
効能
利尿薬, アルドステロン拮抗薬
説明
Finerenone is a novel mineralocorticoid receptor antagonist that has the effect of delaying the progression of chronic kidney disease. Some people may be aware of two other mineralocorticoid receptor antagonists: the diuretic antihypertensive drug spironolactone, and eplerenone.Finerenone is their cognate derivative and is a third-generation mineralocorticoid receptor antagonist. So far, finerenone is the only nonsteroidal mineralocorticoid receptor antagonist to be FDA approved. Finerenone was granted FDA approval on 9 July 2021, followed by the EMA approval on 11 March 2022.
brand name
Finerenone is sold under the brand name Kerendia and Firialta.
Mode of action
Finerenone is a Nonsteroidal Mineralocorticoid-Receptor Antagonist. The mechanism of action of finerenone is as a Mineralocorticoid Receptor Antagonist. Finerenone inhibits the effects of mineralocorticoids like aldosterone and cortisol when the MR is overactivated, possibly reducing inflammation and fibrosis in the heart and kidney.
参考文献
Kolkhof, P., Hartmann, E., Freyberger, A., et al.Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage. Am. J. Nephrol. 52(8), 642-652 (2021).
DOI:
10.1159/000516213Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
フィネレノン 上流と下流の製品情報
原材料
準備製品
フィネレノン 生産企業
Global( 222)Suppliers
- 1050477-31-0
- Finerenone (BAY 94-8862)
- BAY948862
- 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-
- (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide
- BAY 94-8862
- Finerone
- Mr Neri ketone
- (S)-4-(4-Cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide
- Finerenone Inn
- Fenaridone
- Finerenone
- inhibit,cardiorenal,systolic,disease,pressure,Finerenone,diabetes,chronic,type,Inhibitor,kidney,Mineralocorticoid Receptor,oral,nonsteroidal,blood
- (DL)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-
- (4S)-4-(4-Cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-1,6-naphthyridine-3-carboxamide (Finerenone Impurity)
- Finerenone API
- Finerenone In-House
- BAY 94-8862 Finerenone
- Fenalidone
- フィネレノン
- フィネレノン (JAN)
- (4S)-4-(4-シアノ-2-メトキシフェニル)-5-エトキシ-2,8-ジメチル-1,4-ジヒドロ-1,6-ナフチリジン-3-カルボキサミド
- 1,4-ジヒドロ-2,8-ジメチル-4β-(2-メトキシ-4-シアノフェニル)-5-エトキシピリド[4,3-b]ピリジン-3-カルボアミド